Innovating targeting Philogen is a Swiss-Italian biotechnology company, founded in 1996 and listed on the Italian Stock Exchange, with a mission to innovate the treatment of cancer and other serious conditions Nov 29 2021 2021, Investors, Press Releases Philogen S.p.A. nomina Mediobanca – Banca di Credito Finanziario S.p.A., quale intermediario incaricato dell’esecuzione del programma di acquisto di azioni proprie More details OUR SCIENCES Learn about our strategy PIPELINE Learn more about our pipeline WORK WITH US Look at open positions Privacy Policy / Cookie Policy Contacts Philogen S.p.A. © Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it Notice We and selected third parties use cookies or similar technologies for technical purposes and, with your consent, for other purposes as specified in the cookie policy. Learn more and customize Reject Accept